Surgical Site Infection
Conditions
Brief summary
This is a safety study to determine the skin sensitization potential of ZuraPrep™ and ZuraPrep™ without isopropyl alcohol (IPA) after repetitive patch applications to skin of human subjects. Indications of both sensitization and skin irritation will be evaluated.
Detailed description
This study is designed to determine if the test product, ZuraPrep™ is a skin sensitizing agent when applied to human skin. The study, a modified Draize skin sensitization evaluation, will be conducted in three discrete phases: 1) induction, 2) rest, and 3) challenge. During the Induction Phase, skin sites are exposed to the test product repeatedly for 21 consecutive days. The Rest Phase, a 14-day period when no treatment is performed, serves to provide adequate time for the immune system to react to ZuraPrep™, given any of its components serve as antigens. During the Challenge Phase, the subjects' skin is re-exposed to the test product (ZuraPrep™) to determine if it is likely to be immunosensitizing.
Interventions
DRUGChloraprep
ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
OTHERZuraPrep without IPA
ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
Sponsors
Zurex Pharma, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects may be of either sex, at least 18 years of age and of any race * Subjects must be free of tattoos, sunburn, dermatoses, cuts, lesions or other disorders of the skin of the back. * Subjects must be in good general health
Exclusion criteria
* Known allergies to latex, metals, tape and/or adhesives, soap, citric acid, methylene blue, methylparaben, propylparaben, chlorhexidine gluconate, isopropyl alcohol, and sodium lauryl sulfate. * Exposure of the back region to antimicrobial agents, medicated soaps, medicated shampoos, medicated lotions, strong detergents, sun-tanning, use of tanning beds, or swimming or soaking in pools or hot tubs, in the 7 days prior to, or during the 3-week test period. * Use of topical or systemic corticosteroid, antihistamine, or anti-inflammatory medications in the 7 days prior to, or during the 3-week test period. * Current or recent severe illness such as asthma, diabetes, hepatitis, organ transplant, mitral valve prolapse, congenital heart disease, internal prostheses, or any immunocompromised condition such as AIDS or HIV positive. * Pregnancy, plans to become pregnant, breast-feeding * Any active skin rash or breaks in the skin of the back * Any sunburn or tattoos on the skin of the back * Current active skin disease or inflammatory skin condition including contact dermatitis * Participation in a clinical study in the past 7 days or current participation in another clinical study * Any medical condition or use of any medications that, in the opinion of the Principal Investigator, would preclude participation * Unwillingness to fulfill the performance requirements of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Skin sites evaluated and graded for irritancy or sensitization | 0-40 days post dose | Only frank sensitization will be categorized, as a positive control (known sensitizing agent) is prohibitive due to ethical considerations/risk of life-time sensitization. Reactions observed will be assessed as to whether indicative of sensitization or of irritation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Statistics of irritation scores | 0-40 days post dose | Irritation scores, relative to the Test Products, Reference Product, and the Negative Control applied to skin on each test day will be compared as well as the total cumulative irritation scores across all test days. |
Countries
United States
Outcome results
None listed